Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness

Summary

This multi-site Phase 3 clinical trial is a randomized, double-blind, placebo-controlled and open label active-controlled study to identify the safety and efficacy of a repeated-dose regimen of DPI-386 nasal gel (intranasal scopolamine gel) for the prevention and treatment of motion sickness. The study will be conducted aboard Navy fleet or Marine ships undergoing military operations to obtain data in an operationally relevant real world environment.

Timeline

Start

2019-04-22

Primary completion

2020-06

Completion

2020-07

Drugs

Indications